Home › Research › Biomarkers
Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment
Sergio Cammarata, Roberta Borghi, Luca Giliberto, Matteo Pardini, Valeria Pollero, Cristina Novello, Michele Fornaro, Antonella Vitali et al.. Journal of Alzheimer's disease : JAD, 2009
Topic: Plasma and spinal-fluid biomarkers
Amnestic mild cognitive impairment (aMCI) is considered a prodromal stage of Alzheimer's disease (AD). We measured plasma levels of amyloid-beta40 (Abeta40) and Abeta42 in 191 subjects with aMCI. Seventy-nine of them were clinically followed for two years. In the total cohort of aMCI cases, the average level of Abeta42, as well as the Abeta42/Abeta40 ratio, was significantly higher than those of the 102 cognitively normal age-matched subjects. The aMCI cases that converted to probable AD within 2 years had higher levels of Abeta42 and, to a lesser extent, Abeta40 than the stable cases. However the large variability of measured values indicates that plasma Abeta is not a suitable marker of incipient AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cammarata, S., Borghi, R., Giliberto, L., Pardini, M., Pollero, V., Novello, C., et al. (2009). Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-2009-1144
Vancouver
Cammarata S, Borghi R, Giliberto L, Pardini M, Pollero V, Novello C, et al. Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. Journal of Alzheimer's disease : JAD. 2009. doi:10.3233/jad-2009-1144. PMID: 19584444.
BibTeX
@article{cammarata2009-19584444,
author = {Cammarata, Sergio and Borghi, Roberta and Giliberto, Luca and Pardini, Matteo and Pollero, Valeria and Novello, Cristina and Fornaro, Michele and Vitali, Antonella and others},
title = {{Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2009},
doi = {10.3233/jad-2009-1144},
pmid = {19584444},
url = {https://doi.org/10.3233/jad-2009-1144}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In the total cohort of aMCI cases, the average level of Abeta42, as well as the Abeta42/Abeta40 ratio, was significantly higher than those of the 102 cognitively normal age-matched subjects.
- However the large variability of measured values indicates that plasma Abeta is not a suitable marker of incipient AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants191
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 28 of the 56 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 191 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19584444) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 28 of the 56 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Biomarkers
Also in Biomarkers
204 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.